Skip to main content
Equibles
CVM logo

CVM · Cel Sci Corp · Metrics

Track CVM — free

Use CVM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CVM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.31 +0.22 (+10.53%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 14, 2026
Market Cap
$36.24M
Shares
17.59M
Volume · Oct 2 374.82K Avg daily vol (3M) 241.58K

CVM metrics

60 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.09
Market cap
$36.24M

Price action

20 metrics
Price change (1W)
+21.5%
Price change (30D)
+26.7%
Price change (3M)
+83.3%
Price change (6M)
-39.8%
Price change (YTD)
-60.3%
Price change (1Y)
-79.0%
Trailing year
Price change (5Y)
—
52-week high
$10.47
52-week low
$0.97
Change from 52-week high
-80.0%
Change from 52-week low
+115.5%
Annualized volatility
106.0%
Annualized volatility (3M)
88.2%
Beta
1.5
RSI (14D)
76.5
Price vs SMA 50
+36.5%
Price vs SMA 200
-27.6%
Avg volume (3M)
241,575
Relative volume
3.4
Average dollar volume
$344,094

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
17.59M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
137.3×
reciprocal yield 0.7%
P / book
3.3
reciprocal yield 30.2%
FCF yield
-46.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-62.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-9,721.4%
Trailing 12 months
Net margin
-10,359.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$22.29M
Net income (TTM)
−$22.70M
Trailing 12 months
Diluted EPS (TTM)
$-1.15
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.14
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.99

Growth

11 metrics
Revenue growth YoY
+339.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$264,033
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+191.9%
Year over year · more shares
Revenue CAGR (3Y)
-34.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-207.2%
Return on assets
-106.3%
Debt / equity
—
Current ratio
1.5
EBITDA (TTM)
−$20.29M
Free cash flow (TTM)
−$16.75M
Quick ratio
—
Interest coverage
-50.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$6.53M
Total assets
$21.36M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$16.75M
Capital expenditures (TTM)
$5,155
R&D (TTM)
$14.80M
SG&A (TTM)
—
Stock compensation (TTM)
$1.79M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
40
13F filer change QoQ
+1
Institutional ownership
11.3%

Short interest

3 metrics
Short interest
3.5%
Latest settlement · 5.6 days to cover
Days to cover
5.6d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
$138,000
Insider-sentiment score
84 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 725363 CUSIP 150837706 13F (30d) 2 filings 2 filers Visit website Investor relations